Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>Products>This Product

Covance, Inc.

Product Description

Covance, with headquarters in Princeton, New Jersey, is one of the world’s largest and most comprehensive drug development services companies, with annual revenues greater than $2 billion, employees in more than 60 countries, and more than 11,000 employees worldwide.

Nonclinical Development: Toxicology, Research Products, Analytical Services

• Managed 443 compound development programs (>250 IND/CTA enabling), with  over 100 different sponsors, which led to 41 IND/CTA applications in 2009
• Performed best-in-class productivity cycle times: FIA to FIH in 22 weeks
• Dedicated Capacity Agreements with several major pharma customers
• Greater than 2.5M sq ft of research space

Clinical Development: Clinical Pharmacology, Clinical, Central Labs

• Supported 50% of latest breakthrough cancer treatments
• Supported development of the top 25 currently marketed medicines
• 70% of clinical programs on or ahead of enrollment timelines
• Broad-based, scalable and market-leading, Biomarker capability
• 99% of samples received within stability
• 145 million laboratory tests; 83,000 investigator sites; 100 countries
• Seven Clinical Pharmacology units with ~500 beds

Periapproval & Market Access

• Results-driven reimbursement support for >60% of the biologics market
• Designed and managed world’s largest safety registry ever – iPledge
• Team of experts dedicated to risk management and Pharmacovigilance
• Bi-coastal call center capabilities to deliver patient and physician support
Product Covance, Inc.
Company Covance - Service Directory
Price Request a quote
More Information View company product page
Catalog Number Unspecified
Quantity Unspecified
Company Logo

Covance - Service Directory
210 Carnegie Center Princeton, New Jersey 08540 United States

Tel: +1.888.268.2623

Scientific News
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Designing Drugs with a Whole New Toolbox
Researchers develop methods to design small, targeted proteins with shapes not found in nature.
Small Molecules Lead to a Big Change in Reaction Outcomes
Scientists have changed the behaviour of a group of molecules involved in carbon-oxygen bond synthesis.
Targeting Fat to Treat Cancer
Researchers develop novel cancer treatment that halts fat synthesis in cells, stunting tumors.
Hyperstable Peptides for 'On-Demand' Drugs
These small molecules can fold into different conformations that could allow for greater flexibility in precision drug design
Drug Leads Identified to Combat Heart Disease
Using three supercomputers, researchers surveyed protein structures through accelerated molecular dynamics.
Accelerating the Path to Molecules for Medicine
Researchers convert carbon-hydrogen bonds into nitriles - converting organic molecules into components of medicines.


Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos